SCHEMBL4296958

SCHEMBL4296958

C[C@@H]1CN(Cc2ccc(Nc3ncc4ccn(-c5cc(F)c(C(=O)N6CCOCC6)c(F)c5)c4n3)cc2)C[C@H](C)N1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RPS6KA3 P51812 2/20 0.47
STAT6 P42226 6/20 0.46
JAK3 P52333 3/20 0.44
JAK2 O60674 6/20 0.43
BRD4 O60885 6/20 0.43
MLNR O43193 2/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
GHSR Q92847 1/20 0.42
JAK1 P23458 1/20 0.41
BRD2 P25440 1/20 0.41
BRD3 Q15059 1/20 0.41
BRDT Q58F21 1/20 0.41
EGFR P00533 1/20 0.41
AURKA O14965 1/20 0.41
AURKB Q96GD4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4296954 1.00 RPS6KA3 (0.47) RPS6KA3STAT6JAK3JAK2BRD4
SCHEMBL4291476 0.90 RPS6KA3 (0.53) RPS6KA3STAT6JAK3JAK2BRD4
SCHEMBL13749853 0.89 STAT6 (0.49) RPS6KA3STAT6JAK3JAK2BRD4
SCHEMBL1657628 0.88 RPS6KA3 (0.49) RPS6KA3STAT6JAK3JAK2BRD4
SCHEMBL4291720 0.88 JAK2 (0.51) RPS6KA3STAT6JAK3JAK2BRD4
SCHEMBL1655662 0.88 JAK3 (0.49) RPS6KA3STAT6JAK3JAK2BRD4
SCHEMBL1655278 0.88 RPS6KA3 (0.45) RPS6KA3STAT6JAK3JAK2BRD4
SCHEMBL1655855 0.87 JAK2 (0.53) RPS6KA3STAT6JAK3JAK2BRD4
SCHEMBL1657484 0.86 RPS6KA3 (0.49) RPS6KA3STAT6JAK3JAK2BRD4
SCHEMBL1657486 0.86 RPS6KA3 (0.49) RPS6KA3STAT6JAK3JAK2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 US claimed
US-8420657-B2 Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors NOVARTIS AG (CH) 2013-04-16 US disclosed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 US disclosed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 US disclosed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203688-A1 HETEROCYCLIC COMPOUNDS ABL1, JAK2, JAK1 RPS6KA3 303/4885STAT6 601/4885JAK3 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.